Investigator Grant Management at Scale: How Large Sponsors are Taking Control

Managing investigator grants across large portfolios isn't just a tracking problem. It's a trial oversight issue. Large portfolios mean exponential complexity. The result? Limited visibility into site and procedural-level liabilities that make it nearly impossible to accurately forecast and estimate investigator expenses (which can be over 50% of a trial's budget). Incorrect billing and surprise invoices also get more common without clear oversight over the financial aspects of your trial.

The good news: Sponsors already have the data they need to better manage their investigator spend, even with large portfolios. In this session, we'll walk through how.

Join us to learn how leading pharma and biotechs are:

• Managing investigator spend using data they already have
• Building data taxonomies and ontologies to organize and harmonize their data
• Using new technology and automation to operate at scale